Evidence map›Paper›PMID 37979093›Full record

ArticleJournal of neurology2024

Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88

Alexandre Guérémy, José Boucraut, John Boudjarane, Aude-Marie Grapperon, Etienne Fortanier, Laure Farnault, Jean Gabert, Frédéric Vely, Romaric Lacroix, Ludivine Kouton and 2 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Frequency and Relevance of MYD88European journal of neurology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Alexandre GuérémyReferral Centre for Neuromuscular Diseases and ALS, Hospital La Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
José BoucrautAPHM, Hôpital de La Timone, Service d'Immunologie, Marseille-Immunopole, Marseille, France.
John BoudjaraneLaboratory of Constitutional Cytogenetics, Department of Medical Genetics, La Timone Hospital Marseille, Marseille, France.
Aude-Marie GrapperonReferral Centre for Neuromuscular Diseases and ALS, Hospital La Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
Etienne FortanierReferral Centre for Neuromuscular Diseases and ALS, Hospital La Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
Laure FarnaultHaematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille, France.
Jean GabertINT Bd Jean Moulin Aix-Marseille University UMR7289, Marseille, France.
Frédéric VelyAPHM, Hôpital de La Timone, Service d'Immunologie, Marseille-Immunopole, Marseille, France.
Romaric LacroixCenter for CardioVascular and Nutrition Research (C2VN), Faculty of Medical and Paramedical Sciences, Aix-Marseille University, National Institute of Health and Medical Research (INSERM), National Research Institute for Agriculture, Food and Environment (INRAE), 13005, Marseille, France.
Ludivine KoutonReferral Centre for Neuromuscular Diseases and ALS, Hospital La Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
Shahram AttarianReferral Centre for Neuromuscular Diseases and ALS, Hospital La Timone, 264 Rue Saint Pierre, 13005, Marseille, France.
Emilien DelmontReferral Centre for Neuromuscular Diseases and ALS, Hospital La Timone, 264 Rue Saint Pierre, 13005, Marseille, France. emilien.delmont@ap-hm.fr.ORCID http://orcid.org/0000-0002-5591-2774
Hôpital de la Timone · FRCentre National de la Recherche Scientifique · FRHôpital de la Conception · FRInserm · FRInstitut de Neurosciences des Systèmes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAnti-MAG neuropathies are associated with an IgM monoclonal gammopathy of undetermined significance (MGUS) or with a malignant haemopathy. Our objective was to determine whether the presence of a haemopathy or somatic mutations of MYD88 and CXCR4 genes influences disease presentation and response to rituximab (RTX).

methodsWe included 79 patients (mean age 74 years, disease duration 9.68 years) who had a bone marrow aspiration with morphologic and immunophenotypic analysis. MYD88

resultsMalignant haematological disorders were discovered in 17 patients (22%): 13 Waldenstrom macroglobulinemia, 3 marginal zone lymphoma and one mantle cell lymphoma. MYD88

conclusionsMYD88

Indexed as

LymphomaMonoclonal Gammopathy of Undetermined SignificanceWaldenstrom MacroglobulinemiaAdultAgedHumansImmunoglobulin MMutationMyeloid Differentiation Factor 88Receptors, CXCR4CXCR4 protein, humanImmunoglobulin MMYD88 protein, humanMyeloid Differentiation Factor 88Receptors, CXCR4Anti-MAGBiologicalClinicalElectrophysiologicalHaemopathyMYD88

Identifiers

PMID37979093
OpenAlexW4388795172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.